GLP-1 Drugs: What the Transcripts Say About the Side Effects

What Are GLP-1 Drugs?

GLP-1 — glucagon-like peptide-1 — is a hormone naturally produced in the gut after eating. It signals satiety to the brain, slows gastric emptying, and prompts the pancreas to release insulin in response to food. GLP-1 receptor agonist drugs (semaglutide sold as Ozempic and Wegovy; tirzepatide sold as Mounjaro and Zepbound; liraglutide sold as Saxenda) mimic this hormone at pharmacological doses to suppress appetite and produce weight loss.

Novo Nordisk's GLP-1 drugs generated over $28 billion in revenue in 2024 alone. Approximately 6% of American adults are currently on one of these drugs, with projections suggesting that number could reach 9% — roughly 31 million people — by 2035. The scale of adoption means the long-term side effect profile matters enormously. What follows is drawn from patient experiences and practitioner commentary across hundreds of hours of transcripts from doctors and patients in the metabolic health space.

1. Gastroparesis — Stomach Paralysis

GLP-1 drugs work in part by slowing gastric emptying — food moves from the stomach into the small intestine more slowly, which prolongs the feeling of fullness. At therapeutic doses, this mechanism is the feature. At high doses, or with prolonged use, it can become a serious problem: gastroparesis, or partial to complete paralysis of the stomach.

One patient who used GLP-1 drugs for diabetes for over a year reported the consequence directly:

"It had not helped me for the weight, had not helped me for the sugar control, but gave me macular edema. And it had given me as well gastroparesis."
— Patient account, ZeroCarb community

Another patient who came off GLP-1 drugs expressed a broader concern about gut effects:

"I do kind of fear long-term side effects from the GLPs. There's not a lot of research on long-term. Short-term it can mess with just intestines overall — paralysed intestines, all sorts of weird stuff. Also, muscle mass."
— Patient account, ZeroCarb community

Gastroparesis symptoms include nausea, vomiting, bloating, early satiety, and in severe cases, the inability to keep food down at all. Cases of severe gastroparesis requiring hospitalisation have been reported in patients who had no prior history of the condition before starting GLP-1 therapy.

2. Muscle Mass Loss

Weight loss on GLP-1 drugs is not purely fat loss. Studies and patient reports consistently show a significant proportion of the weight lost is lean muscle mass — in some trials, up to 40% of total weight lost. This is biologically significant: muscle drives metabolic rate, insulin sensitivity, and long-term functional health.

One patient using a high-strength GLP-1 drug while also doing carnivore expressed the concern plainly:

"I'm concerned I'm actually not getting enough calories a day right now... That's also when I'll have my next BIA scan so I can make sure I'm not losing muscle mass."
— Patient account, ZeroCarb community

When appetite is suppressed to near-zero, the body cannot prioritise protein intake. Without adequate protein and resistance stimulus, muscle wasting follows weight loss. The result can be a person who is lighter on the scale but metabolically weaker — less able to regulate blood sugar, more prone to future fat gain, and physically frailer.

3. Thyroid Risk

GLP-1 receptors are expressed in thyroid tissue. In animal studies, GLP-1 agonists caused dose-dependent thyroid C-cell tumours, including medullary thyroid carcinoma (MTC). The FDA includes a black-box warning on all GLP-1 drugs for this risk, and they are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2.

One patient with a strong family history of thyroid conditions noted the risk specifically:

"It also comes with adherent thyroid risks because of the way your body absorbs the medication. And even though I have a family history of thyroid — a father who's hypo, a mother who had cancer, a grandmother who is hyper-hypo."
— Patient account, ZeroCarb community

Whether the thyroid risk observed in rodents translates fully to humans at prescribed doses remains debated, but the regulatory warning exists for a reason, and patients with thyroid history are explicitly excluded from these drugs by prescribing guidelines.

4. Macular Oedema and Eye Complications

Rapid changes in blood glucose levels — which GLP-1 drugs can produce — are known to affect the retinal vasculature. Macular oedema (swelling at the centre of the retina) has been reported in patients on GLP-1 therapy, including in patients who did not have prior diabetic retinopathy.

The patient quoted above in the gastroparesis section experienced both side effects simultaneously despite the drug having no measurable effect on either their weight or blood sugar (A1C was 6.7 before starting and remained at 6.7 after eighteen months of use):

"So it had not helped me for the weight, had not helped me for the sugar control, but gave me macular edema. And it had given me as well gastroparesis."
— Patient account, ZeroCarb community

5. "Ozempic Face" — Accelerated Facial Ageing

Rapid weight loss — regardless of method — preferentially draws on subcutaneous facial fat, which provides the structure and volume that gives faces a youthful appearance. On GLP-1 drugs, where weight loss can be dramatic and fast, this effect is pronounced enough that it has acquired a clinical nickname: Ozempic face. Patients describe looking gaunt, hollowed, and significantly older despite being lighter.

"They say people develop Ozempic face. And looking back, yeah, maybe there was an element of that with me, because people said, 'You look ill. You've lost all this weight.' I lost like 10% of my body weight. The last few weeks of it I felt awful."
— Patient account, ZeroCarb community

6. Forced Starvation and Nutritional Deficiency

At the doses typically prescribed — which practitioners in the transcripts consistently describe as far too high — GLP-1 drugs can eliminate appetite almost entirely. Patients describe having to force themselves to eat. The problem is that the small amount of food consumed is rarely nutritionally adequate, particularly in protein, fat-soluble vitamins, and minerals.

"I had no appetite whatsoever. Like I'd have to force myself to eat some food."
— Patient account, ZeroCarb community

"I see someone that they don't eat barely 500 calories and it's like a croissant. You're not actually getting the nutrition that you might need."
— Patient account, ZeroCarb community

Caloric restriction at this extreme, without nutritional density, is a form of accelerated malnutrition. Deficiencies in fat-soluble vitamins (A, D, K2, E), omega-3s, zinc, and B12 accumulate silently under the pharmacological appetite suppression.

7. Hormonal Disruption

GLP-1 receptors are not confined to the gut and pancreas — they are expressed widely across the body, including in the brain, heart, kidneys, and reproductive system. Pharmacological GLP-1 stimulation at sustained high doses disrupts hormonal signalling beyond the intended targets.

"Look at these GLP-1 weight loss products for example. Yeah, you lose a bunch of weight, but it totally screws up your hormones and everything else along with that."
— Patient account, ZeroCarb community

8. The Craving Return at Two Years

Perhaps the most underreported finding in the GLP-1 literature is what happens at the two-year mark. Research tracking patients on GLP-1 agonists shows that the appetite suppression and craving reduction that characterise early use begin to reverse after approximately two years, with cravings returning to near-baseline levels spontaneously:

"As we follow people on GLP-1 agonists for up to 24 months, what was control of cravings starts to go away at around two years in. Cravings start to come back naturally on their own."
— Dr Shawn Baker MD

This means the primary mechanism of action — appetite suppression — is not permanent even with continued use. Tolerance develops. The drug keeps costing money, keeps carrying its side effect profile, but the main clinical benefit erodes.

9. Weight Rebounds When Stopped

The most consistent finding in GLP-1 discontinuation studies is weight regain. Without the pharmacological appetite suppression, and without any dietary habits having been built during the drug's use, virtually all patients regain the lost weight — and often more — within a year of stopping.

"Once you get off those products, you don't have the foundations to keep that weight off. You go back to your bad habits and gain all that weight back again."
— Patient account, ZeroCarb community

The drug suppresses appetite pharmacologically but does nothing to address the dietary patterns — specifically carbohydrate-driven insulin cycles — that caused the weight gain in the first place. The metabolic environment resumes the moment the drug is withdrawn.

10. A Drug You Take Forever

Given the rebound on discontinuation, the commercial reality of GLP-1 drugs is that they must be taken indefinitely to maintain effect:

"They come up with a great treatment for a disease — like a GLP-1 that you've got to take for the rest of your life — the stockholders win. Unfortunately, your health doesn't get better, but they want customers."
— Patient account, ZeroCarb community

At $1,000 or more per month, lifelong GLP-1 therapy represents a significant financial commitment alongside its cumulative side effect exposure. Dr Shawn Baker put it plainly:

"You could certainly do that — at the cost of $1,000 a month for the rest of your life. Not to mention there's a significant side effect profile. A lot of people are going to be seriously injured by these drugs."
— Dr Shawn Baker MD

Your Body Already Makes GLP-1 Naturally

What is rarely discussed in mainstream coverage of these drugs is that the body has its own GLP-1 system — and a species-appropriate, low-carbohydrate diet activates it naturally. Research cited by Dr Shawn Baker shows that beef directly stimulates GLP-1 receptors in the human gut in a physiologically appropriate way:

"There are great studies that show that beef actually stimulates GLP-1 in the human body in a physiologically appropriate way. What is the GLP-1? That's what causes the weight loss. GLP-1 stands for glucagon-like peptide. If they just would change their diet, they could get that effect — and actually get it even better. It feels like having an actual GLP-1 agonist just by cutting out carbohydrates."
— Dr Shawn Baker MD

The distinction matters: dietary GLP-1 stimulation is self-regulating, proportionate to what the body needs, carries no exogenous side effect profile, costs nothing, and builds metabolic habits that last after the meal ends. Pharmacological GLP-1 agonism overrides the body's own system at a fixed dose, indefinitely.

Summary of Key Side Effects